The Impact of Metabolic Syndrome on Disease Activity in Patients with Rheumatoid Arthritis at Nguyen Tri Phuong Hospital
Main Article Content
Abstract
Rheumatoid arthritis (RA) is a chronic autoimmune disease closely associated with metabolic disorders and an increased risk of cardiovascular disease. Metabolic syndrome (MetS) is commonly observed in RA patients and may influence both disease activity and treatment response. A descriptive cross-sectional study was conducted on 152 RA patients diagnosed according to the 2010 ACR/EULAR criteria who were being followed and treated at Nguyen Tri Phuong Hospital between May and September 2025. The prevalence of MetS, based on the JC 2009 criteria, was found to be 26.3%. Patients with metabolic syndrome showed higher disease activity and inflammatory markers compared to those without the syndrome; however, these differences did not reach statistical significance. Metabolic syndrome is an important issue in RA patients, as it not only increases the burden of cardiovascular diseases but may also affect disease progression and treatment outcomes.
Article Details
Keywords
Rheumatoid arthritis, metabolic syndrome, disease stage
References
2. Đào Hùng Hạnh, Đỗ Quỳnh Trang, Sakamoto J. Increased frequency of metabolic syndrome among Vietnamese women with early rheumatoid arthritis: a cross-sectional study. 2010; 12(6)R218. doi:10.1186/ar3203.
3. Barry S, Sheng E, Baker JF. Metabolic Consequences of Rheumatoid Arthritis. Arthritis Care Res (Hoboken). Oct 2025; 77(10): 1167-1174. doi:10.1002/acr.25537.
4. Kay J, Upchurch KS. ACR/EULAR 2010 rheumatoid arthritis classification criteria. Rheumatology (Oxford). Dec 2012; 51 Suppl 6:vi5-9. doi:10.1093/rheumatology/kes279.
5. Bhattacharya PK, Barman B, Jamil M, Bora K. Metabolic Syndrome and Atherogenic Indices in Rheumatoid Arthritis and their Relationship with Disease Activity: A Hospital-based Study from Northeast India. J Transl Int Med. Jun 2020; 8(2): 99-105. doi:10.2478/jtim-2020-0015.
6. Johnson TM, Michaud K, England BR. Measures of Rheumatoid Arthritis Disease Activity. Arthritis Care Res (Hoboken). Oct 2020; 72 Suppl 10(Suppl 10): 4-26. doi:10.1002/acr.24336.
7. Faiz KW. [VAS--visual analog scale]. Tidsskr Nor Laegeforen. Feb 11 2014; 134(3): 323. VAS--visuell analog skala. doi:10.4045/tidsskr.13.1145.
8. Anderson JK, Zimmerman L, Caplan L, Michaud K. Measures of rheumatoid arthritis disease activity. Arthritis Care Res (Hoboken). Nov 2011; 63 Suppl 11: S14-36. doi:10.1002/acr.20621.
9. Kassi E, Pervanidou P, Kaltsas G, Chrousos G. Metabolic syndrome: definitions and controversies. BMC Med. May 5 2011;9:48. doi:10.1186/1741-7015-9-48
10. Đặng Kim Anh, Lê Thi Hương, Nguyễn Thu Giang và cộng sự. Prevalence of metabolic syndrome and its related factors among Vietnamese people: A systematic review and meta-analysis. Diabetes Metab Syndr. Apr 2022; 16(4): 102477. doi:10.1016/j.dsx.2022.102477.
11. Zhou Y, Gao J. Association between metabolic score for insulin resistance and cardiovascular disease mortality in patients with rheumatoid arthritis: evidence from the NHANES 1999-2018. Front Endocrinol (Lausanne). 2024; 15: 1444800. doi:10.3389/fendo.2024.1444800.
12. Grzechnik K, Targońska-Stępniak B. Metabolic Syndrome and Rheumatoid Arthritis Activity: An Analysis of Clinical, Laboratory, and Ultrasound Parameters. Nutrients. Nov 12 2023; 15(22). doi:10.3390/nu15224756.
13. Burli A, Dave M. Clinical & Demographic Profile and Prevalence of Metabolic Syndrome Among Patients with Rheumatoid Arthritis and its Correlation with Disease Activity. The Journal of the Association of Physicians of India. 04/01 2022; 70:11-12.
14. Xie W, Yang X, Ji L, Zhang Z. Incident diabetes associated with hydroxychloroquine, methotrexate, biologics and glucocorticoids in rheumatoid arthritis: A systematic review and meta-analysis. Semin Arthritis Rheum. Aug 2020; 50(4): 598-607. doi:10.1016/j.semarthrit.2020.04.005.
15. Smolen JS, Landewé RBM, Bergstra SA, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Annals of the Rheumatic Diseases. 2023; 82(1): 3. doi:10.1136/ard-2022-223356.